Oncternal Therapeutics Inc (ONCT)

$8.66

-0.16

(-1.87%)

Market is closed - opens 7 PM, 20 May 2024

Insights on Oncternal Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 106.0K → 569.0K (in $), with an average increase of 42.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -9.86M → -8.38M (in $), with an average increase of 8.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 54.7% return, outperforming this stock by 14.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 226.3% return, outperforming this stock by 318.3%

Performance

  • $8.54
    $8.95
    $8.66
    downward going graph

    1.4%

    Downside

    Day's Volatility :4.57%

    Upside

    3.22%

    downward going graph
  • $5.57
    $13.14
    $8.66
    downward going graph

    35.68%

    Downside

    52 Weeks Volatility :57.61%

    Upside

    34.09%

    downward going graph

Returns

PeriodOncternal Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
0.7%
0.8%
0.0%
6 Months
24.07%
13.4%
0.0%
1 Year
40.63%
11.4%
0.0%
3 Years
-91.98%
17.7%
-19.9%

Highlights

Market Capitalization
26.1M
Book Value
$10.19
Earnings Per Share (EPS)
-12.33
Wall Street Target Price
27.67
Profit Margin
0.0%
Operating Margin TTM
-1542.88%
Return On Assets TTM
-49.48%
Return On Equity TTM
-86.75%
Revenue TTM
1.2M
Revenue Per Share TTM
0.39
Quarterly Revenue Growth YOY
180.29999999999998%
Gross Profit TTM
-31.5M
Diluted Eps TTM
-12.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-10.47
EPS Estimate Next Year
-8.44
EPS Estimate Current Quarter
-2.88
EPS Estimate Next Quarter
-2.6

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Oncternal Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
3
4
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 219.52%

Current $8.66
Target $27.67

Technicals Summary

Sell

Neutral

Buy

Oncternal Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oncternal Therapeutics Inc
Oncternal Therapeutics Inc
1.29%
24.07%
40.63%
-91.98%
732.69%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oncternal Therapeutics Inc
Oncternal Therapeutics Inc
NA
NA
NA
-10.47
-0.87
-0.49
NA
10.19
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oncternal Therapeutics Inc
Oncternal Therapeutics Inc
Buy
$26.1M
732.69%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • Vanguard Group Inc

    4.83%
  • Millennium Management LLC

    3.47%
  • BlackRock Inc

    1.33%
  • Richmond Brothers Inc

    0.83%
  • Renaissance Technologies Corp

    0.55%
  • LPL Financial Corp

    0.29%

Corporate Announcements

  • Oncternal Therapeutics Inc Earnings

    Oncternal Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic

Organization
Oncternal Therapeutics Inc
Employees
27
CEO
Dr. James B. Breitmeyer M.D., Ph.D.
Industry
Biotechnology

FAQs